GLP-1 gallbladder risk

What the trial signal looks like

Both the semaglutide (STEP) and tirzepatide (SURMOUNT) trial programmes reported increased rates of cholelithiasis (gallstones) and cholecystitis (gallbladder inflammation) in treatment arms vs placebo. The rates are not high in absolute terms — typically single-digit percentages over trial duration — but they consistently exceed placebo.

Post-marketing reports across the GLP-1 class have reinforced the signal. The prescribing information for Wegovy, Mounjaro, and Saxenda all include gallbladder disease as a recognised adverse effect.

Why this happens

Two mechanisms contribute:

• Slowed gallbladder motility. GLP-1 receptor activation reduces gallbladder emptying frequency. Bile that sits longer is more likely to form stones.
• Rapid weight loss. Independent of any medicine, losing weight quickly is a known gallstone risk factor (cholesterol mobilisation, gallbladder dysmotility during weight loss). The medicine and the weight loss it causes both push in the same direction.

Symptoms to recognise

• Right-upper-quadrant abdominal pain.
• Pain radiating to the right shoulder or right side of the back.
• Pain triggered or worsened by fatty meals.
• Nausea, vomiting.
• Fever.
• Jaundice (yellowing of skin or whites of eyes).
• Dark urine, pale stools.

When to seek urgent care

• Severe right-upper-quadrant pain that doesn’t settle in a few hours.
• Pain with fever, jaundice, or signs of sepsis (high heart rate, low blood pressure, confusion).
• Persistent vomiting alongside abdominal pain.

NHS 111 for non-emergency, 999 or A&E for severe presentations.

Risk reduction in practice

• Don’t lose weight faster than your prescriber and the medicine intend. The titration schedule isn’t arbitrary; it’s designed for tolerability and to keep weight-loss rate within a safer range.
• Maintain protein intake during weight loss. Adequate protein helps maintain lean mass and reduces some of the cholesterol-mobilisation risk.
• Stay hydrated. Adequate fluid supports biliary function.
• Tell your prescriber if you’ve had gallstones before. Past gallstone history doesn’t necessarily preclude GLP-1 use but should be in the clinical picture.

If gallbladder disease develops

Pausing the medicine until imaging clarifies the situation is common. Definitive treatment for symptomatic gallstones is usually cholecystectomy (gallbladder removal). Resuming GLP-1 therapy after cholecystectomy is generally possible but is a clinical decision.